Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial (Q38443075)

From Wikidata

Jump to navigation Jump to search

scientific article published on 08 October 2013

Language	Label	Description	Also known as
English	Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial	scientific article published on 08 October 2013

Statements

scholarly article

1 reference

Europe PubMed Central

3 September 2017

Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial (English)

1 reference

Europe PubMed Central

3 September 2017

0 references

1 reference

based on heuristic

inferred from title

5

object named as

Chloe Orkin

1 reference

Europe PubMed Central

3 September 2017

1

object named as

Marta Boffito

1 reference

Europe PubMed Central

3 September 2017

author name string

Julie Fox

2

1 reference

Europe PubMed Central

3 September 2017

Christine Bowman

3

1 reference

Europe PubMed Central

3 September 2017

Martin Fisher

4

1 reference

Europe PubMed Central

3 September 2017

Edmund Wilkins

6

1 reference

Europe PubMed Central

3 September 2017

Akil Jackson

7

1 reference

Europe PubMed Central

3 September 2017

Olga Pleguezuelos

8

1 reference

Europe PubMed Central

3 September 2017

Stuart Robinson

9

1 reference

Europe PubMed Central

3 September 2017

Gregory A Stoloff

10

1 reference

Europe PubMed Central

3 September 2017

Wilson Caparrós-Wanderley

11

1 reference

Europe PubMed Central

3 September 2017

language of work or name

0 references

publication date

8 October 2013

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

31

1 reference

Europe PubMed Central

3 September 2017

48

1 reference

Europe PubMed Central

3 September 2017

5680-5686

1 reference

Europe PubMed Central

3 September 2017

HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Adverse effects of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Immunotherapies in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Comprehensive analysis of unique cases with extraordinary control over HIV replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Hitting HIV where it hurts: an alternative approach to HIV vaccine design.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Evolutionary and immunological implications of contemporary HIV-1 variation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Multiple sequence alignment with the Clustal series of programs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Expression of a novel Nef epitope on the surface of HIV type 1-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Downregulation of HLA class I antigen expression in CD4+ T lymphocytes from HIV type 1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Nef-mediated enhancement of cellular activation and human immunodeficiency virus type 1 replication in primary T cells is dependent on association with p21-activated kinase 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.057

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.09.057

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38443075&oldid=1760099343"